The following stories appear in full on today's Vidyya Medical News Service Web site.
The FDA today approved a laser system to improve a physician's ability to distinguish small harmless growths from pre-cancerous growths in the colon.
FDA has approved Trizivir for the treatment of HIV in adults and adolescents. Each dose of Trizivir is a fixed-dose combination of Ziagen (abacavir/ABC), Retrovir (zidovudine/AZT), and Epivir (lamivudine/3TC), three nucleoside reverse transcriptase inhibitors (NRTIs) already approved by FDA. Trizivir is not recommended for treatment in adults or adolescents who weigh less than 40 kilograms because it is a fixed-dose tablet.
Trizivir is indicated alone or in combination with other antiretroviral agents for the treatment of HIV infection and it is intended only for patients whose regimen would otherwise include abacavir, lamivudine, and zidovudine. Where possible, Vidyya strives to provide you with prescribing information for new drug approvals. Get information for Trizivir in today's issue.
Today 16 November 2000, the American Cancer Society (ACS) will sponsor its annual "Great American Smokeout" (GASO) to encourage approximately 52 million adult and adolescent smokers in the United States to quit smoking for at least one day. Clinicians ready to help smokers kick the habit can read "Treating Tobacco Use and Dependence A Clinical Practice Guideline" in today's issue.
Pfizer Inc reported yesterday that a new clinical study showed patients treated with LIPITOR(R) (atorvastatin calcium) following an acute coronary syndrome (ACS) experienced fewer subsequent events than those treated with placebo. Results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study were presented yesterday at the 73rd Scientific Sessions of the American Heart Association.
The results of the MIRACL trial demonstrated a positive
effect of the early use of new generation statin therapy. Combined ischemic
events were significantly reduced in the total study population with unstable
angina or non-Q-wave myocardial infarction. While these results provide a
valuable addition to knowledge of the treatment of post-MI patients, they also
raise a number of unanswered questions, including the longer term impact of
aggressive third generation statin therapy on stroke. These points will be
addressed by the PRINCESS trial (Prevention of re-INfarction by early
treatment of CErivaStatin Study).
As always, we hope you enjoy the issue.